T8385

Metoclopramide hydrochloride hydrate (Metoclopramide monohydrochloride monohydrate) is a dopamine D2 antagonist that is a drug used for digestive dysfunction. It acts as an anti-emetic

PTD2, derived from the histone 4 sequence, acts as a peptide inhibitor against Wolf-Hirschhorn syndrome candidate 1 (WHSC1; IC50 = 22 µM), a histone methyltransferase.

Tat-QFNP12 is a peptide that combines a transcriptional transactivator (Tat) transmembrane domain with an inhibitor targeting the interaction between N-Myc downstream regulated gene 2 (NDRG2) and protein phosphatase Mg2+/Mn2+ dependent 1A (PPM1A). This compound effectively mitigates blood-brain barrier endothelial tight junction disruption caused by elevated levels of matrix metalloproteinase-9 (MMP-9), alleviates cerebral edema, and promotes spontaneous activity along with symmetric limb movement in a mouse model of subarachnoid hemorrhage induced by endovascular puncture. These benefits are observed at a dosage of 20 mg/kg.

EGFRvIII peptide, a synthetic peptide mirroring the EGFRvIII fusion junction—a tumor-specific, perpetually active EGFR variant missing amino acids 6-273 of the wild-type—binds to HLA-A*0201-positive T2 cells under MHC class I at 25 µg/ml. It enables antigen presentation in dendritic cells from human peripheral blood mononuclear cells (PBMCs), thus activating CD8+ cytotoxic T lymphocytes and prompting IFN-γ production. Administered at 15 µg/animal with the TLR5 agonist flagellin B, EGFRvIII peptide elevates CD8+ T cell numbers, lowers regulatory T cells (Tregs) in the brain, diminishes tumor volume, and extends survival in a GL261 glioblastoma mouse model.

L-K6L9, a cytolytic peptide comprised of L-isomer leucine and lysine, demonstrates cytotoxicity against both androgen-independent (LNCaP-CL1) and androgen-dependent (22Rv1 and LNCaP) human prostate cancer cells, with LC50 values of 4, 4, and 6 µM, respectively. It also affects non-cancerous cells, including NIH3T3 mouse fibroblasts and OL human foreskin fibroblasts, with LC50s of 7 and 5 µM, respectively. Furthermore, at a concentration of 100 µM, L-K6L9 induces hemolysis in isolated human erythrocytes.

BRC4wt, an acetylated peptide originating from the BRC4 repeat within human BRCA2 (1521-1536), acts as an inhibitor of the BRCA2 and RAD51 protein-protein interaction. When linked to the cationic cell-penetrating peptide (Arg)9, it effectively shortens DNA replication tract lengths and diminishes the frequency of homologous repair of camptothecin-induced DNA damage in vitro. Additionally, BRC4wt enhances the efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib in inducing cell death in HeLa human cervical cancer and U2OS human osteosarcoma cells, albeit it does not affect non-cancerous hTERT RPE-1, MRC-5, or MCF-10A cells.

TG2-179-1 is a BRCA1-associated protein 1 (BAP1) inhibitor with potential anticancer activity. TG2-179-1 exhibits potent cytotoxic activity against colon cancer cells and induces apoptosis. TG2-179-1 can be used in colon cancer research. TG2-179-1 is a BRCA1-associated protein 1 (BAP1) inhibitor with potential anticancer activity.

5α-Pregnane-3α,20α-diol (allopregnanediol) is an endogenous neuroactive steroid metabolite derived from Progesterone metabolism. In animal studies, under specific endocrine conditions (e.g., ovariectomized estrogen-primed rats), it has been shown to modulate gonadotropin release, including stimulation of luteinizing hormone (LH) and suppression of follicle-stimulating hormone (FSH).